Pune Magazine

Primary Myelofibrosis Pipeline Analysis: 55+ Companies | DelveInsight

 Breaking News
  • No posts were found

Primary Myelofibrosis Pipeline Analysis: 55+ Companies | DelveInsight

November 15
01:09 2022
Primary Myelofibrosis Pipeline Analysis: 55+ Companies | DelveInsight

DelveInsight’s, “Primary Myelofibrosis Pipeline Insight, 2022” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Primary Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Primary Myelofibrosis Pipeline Insight Report

  • DelveInsight’s primary myelofibrosis pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for primary myelofibrosis treatment.
  • The leading Primary myelofibrosis companies such as Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Pharmaxis, MorphoSys, Merck & Co, AbbVie, Suzhou Zelgen Biopharmaceuticals, Geron Corporation, Keros Therapeutics, Galecto, Telios Pharma, Chia Tai Tianqing Pharmaceutical Group, Imago BioSciences,  Roche, Incyte Corporation, Disc Medicine, Inc, Bristol-Myers Squibb, Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, Actuate Therapeutics, Samus Therapeutics, Karyopharm Therapeutics, and others are evaluating new drugs for primary myelofibrosis to improve the treatment landscape.
  • Promising primary myelofibrosis pipeline therapies in various stages of development include NS 018, KRT-232, TP 3654, PXS 5505, Pelabresib, ACE-536, Navitoclax, Jaktinib, Imetelstat,  KER-050, GB 2064, TL-895,  TQ05105, Bomedemstat, RO7490677, INCB000928, LDE225,  DISC-0974,  BMS-986158, BMS 986416, LNK01002, PU-H71, TBX-2400, CK0804, ABBV-744,  JAB-8263, Tasquinimod, Mivebresib, 9-ING-41,  Itacitinib, PU-H-71, Selinexor, and others.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Primary myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Primary myelofibrosis.

 

Recent Breakthroughs of the Primary Myelofibrosis Treatment Landscape

  • In June 2022, Cellenkos announced that the US Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application to initiate a Phase Ib, open-label study of CK0804 as an add-on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib.
  • In June 2022, Imago Biosciences presented updated positive data from its ongoing global Phase II clinical study evaluating bomedemstat in patients with advanced myelofibrosis. Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis.
  • In June 2022, announced the US FDA granted Orphan Drug Designation for TP-3654, Sumitomo Pharma Oncology’s proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis.
  • In June 2022, AbbVie announced new data from Cohort 3 of its Phase II REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer. These data reinforced the importance of early intervention in myelofibrosis and the potential to achieve improved clinical outcomes.
  • In February 2022, Active Biotech entered into an exclusive license agreement with Oncode Institute in the Netherlands for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in the treatment of myelofibrosis.

 

Request a sample and discover the recent advances in Primary Myelofibrosis Medication @ Primary Myelofibrosis Treatment Landscape

 

Primary Myelofibrosis Overview

Primary myelofibrosis (also called chronic idiopathic myelofibrosis, agnogenic myeloid metaplasia) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibres on which the stem cells can divide and grow. Specialized cells in the bone marrow known as fibroblasts make these fibres. In primary myelofibrosis, chemicals released by high numbers of platelets and abnormal megakaryocytes (platelet forming cells) over-stimulate the fibroblasts. This results in the overgrowth of thick coarse fibres in the bone marrow, which gradually replace normal bone marrow tissue. Over time this destroys the normal bone marrow environment, preventing the production of adequate numbers of red cells, white cells and platelets. This results in anaemia, low platelet counts and the production of blood cells in areas outside the bone marrow for example in the spleen and liver, which become enlarged as a result. Primary myelofibrosis is a rare chronic disorder diagnosed in an estimated 1 per 100,000 population. It can occur at any age but is usually diagnosed later in life, between the ages of 60 and 70 years. The cause of primary myelofibrosis remains largely unknown. It can be classified as either JAK2 mutation positive (having the JAK2 mutation) or negative (not having the JAK2 mutation).Long-term exposure to high levels of benzene or very high doses of ionizing radiation may increase the risk of primary myelofibrosis in a small number of cases. Around 20 per cent of people have no symptoms of primary myelofibrosis when they are first diagnosed and the disorder is picked up incidentally as a result of a routine blood test. For others, symptoms develop gradually over time. Symptoms of anaemia are common and include unexplained tiredness, weakness, shortness of breath and palpitations.

 

Primary Myelofibrosis Emerging Drugs

NS 018: Nippon Shinyaku

Ilginatinib (formerly NS 018), a potent inhibitor of Janus kinase 2 (JAK2) enzyme activity and Src-family kinases is being developed by Nippon Shinyaku.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Primary Myelofibrosis. 

KRT-232: Kartos Therapeutics

Navtemadlin (KRT-232), is a novel, potent and selective oral MDM2 inhibitor. The MDM2-p53 interaction represents a compelling therapeutic target with potential to provide a new treatment option for patients with Myelofibrosis (MF), Polycythemia Vera (PV), Acute Myeloid Leukemia (AML), and Merkel Cell Carcinoma (MCC).Currently, the drug is in Phase II/III  stage of Clinical trial evaluation for the treatment of Primary Myelofibrosis. 

TP 3654: Sumitomo Pharma Oncology

TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of apoptosis. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Primary Myelofibrosis.

 

Primary Myelofibrosis Pipeline Therapeutic Assessment

There are approx. 55+ key companies which are developing the therapies for Primary myelofibrosis. The companies which have their Primary myelofibrosis drug candidates in the most advanced stage, i.e. Phase II/III include, Kartos Therapeutics.

 

DelveInsight’s report covers around 55+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Learn more about the emerging Primary Myelofibrosis pipeline therapies @ Primary Myelofibrosis Medications

 

Scope of the Primary Myelofibrosis Pipeline Insight Report

  • Coverage- Global
  • Primary Myelofibrosis Pipeline Assessment by Product Type
  • Primary Myelofibrosis Pipeline Assessment by Stage and Product Type
  • Primary Myelofibrosis Pipeline Assessment by Route of Administration
  • Primary Myelofibrosis Pipeline Assessment by Stage and Route of Administration
  • Primary Myelofibrosis Pipeline Assessment by Molecule Type
  • Primary Myelofibrosis Pipeline Assessment by Stage and Molecule Type
  • Primary Myelofibrosis Pipeline Companies- Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Pharmaxis, MorphoSys, Merck & Co, AbbVie, Suzhou Zelgen Biopharmaceuticals, Geron Corporation, Keros Therapeutics, Galecto, Telios Pharma, Chia Tai Tianqing Pharmaceutical Group, Imago BioSciences,  Roche, Incyte Corporation, Disc Medicine, Inc, Bristol-Myers Squibb, Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, Actuate Therapeutics, Samus Therapeutics, Karyopharm Therapeutics, and others
  • Primary Myelofibrosis Pipeline Therapies- NS 018, KRT-232, TP 3654, PXS 5505, Pelabresib, ACE-536, Navitoclax, Jaktinib, Imetelstat,  KER-050, GB 2064, TL-895,  TQ05105, Bomedemstat, RO7490677, INCB000928, LDE225,  DISC-0974,  BMS-986158, BMS 986416, LNK01002, PU-H71, TBX-2400, CK0804, ABBV-744,  JAB-8263, Tasquinimod, Mivebresib, 9-ING-41,  Itacitinib, PU-H-71, Selinexor, and others

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Primary myelofibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Primary myelofibrosis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase II/III)
  8. KRT-232: Kartos Therapeutics
  9. Mid Stage Products (Phase II)
  10. NS 018: Nippon Shinyaku
  11. Early Stage Products (Phase I)
  12. Drug name Company name
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Inactive Products
  16. Primary myelofibrosis Key Companies
  17. Primary myelofibrosis Key Products
  18. Primary myelofibrosis- Unmet Needs
  19. Primary myelofibrosis- Market Drivers and Barriers
  20. Primary myelofibrosis- Future Perspectives and Conclusion
  21. Primary myelofibrosis Analyst Views
  22. Primary myelofibrosis Key Companies
  23. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Primary myelofibrosis drugs?
  • How many Primary myelofibrosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary myelofibrosis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Primary myelofibrosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Primary myelofibrosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Got Queries? Get in touch with our Business Development Executive @ Primary myelofibrosis Market Drivers and Barriers

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories